Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus

Alok Raghav; Jamal Ahmad; Maaz Ozair; Saba Noor; Zeeshan Ahmad Khan; Brijesh Kumar Mishra

doi:doi:10.11648/j.ijde.20160101.13

| Peer-Reviewed |

Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus

Alok Raghav, Jamal Ahmad, Maaz Ozair, Saba Noor, Zeeshan Ahmad Khan, Brijesh Kumar Mishra

Received: 2 November 2016 Accepted: 29 December 2016 Published: 23 January 2017

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Optimal successful management of type 2 diabetes mellitus (T2DM) remains an elusive goal ever. Add on therapies with metformin addressing the prime impaired insulin secretion shows promise in achieving strict and effective glycemic control. The aim of this study was to assess the efficacy of DPP-4 inhibitors, α-glucosidase inhibitors, glitazones and SGLT-2 inhibitors as add-on options with metformin to treat patients with T2DM. The primary outcome of this study was a reduction in diabetes and its associated complication along with strict glycemic control with add-on agents used with metformin.

DOI	10.11648/j.ijde.20160101.13
Published in	International Journal of Diabetes and Endocrinology (Volume 1, Issue 1, December 2016)
Page(s)	13-15
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Diabetes Mellitus, SGLT-2 Inhibitors, Glitazones, α-glucosidase Inhibitors, Metformin

References

[1]	Saydah SH, Fradkin J, Cowie CC. 2004. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291:335–342.
[2]	Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. 2008. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European. Association for the Study of Diabetes. Diabetes Care 31:173–175.
[3]	Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. 2007. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30:753–759.
[4]	DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. 2008. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 31:2315–2317.
[5]	Vilsboll T, Agerso H, Krarup T, et al. 2003. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J ClinEndocrinolMetab, 88:220–4.
[6]	Nathan DM, Davidson MB, DeFronzo RA, et al. 2007. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care, 30:753–9.
[7]	Campbell LK, White JR, Campbell RK. 1996. Acarbose: its role in the treatment of diabetes mellitus. Ann Pharmacother, 30:1255–62.
[8]	Akanuma Y, Kosaka K, Toyoda T, et al. 1996. Clinical evaluation of a new oral hypoglycemic agent CS-045 in combination with insulin [abstract]. Diabetologia; 39 (suppl 1): A232.
[9]	Fonseca VA, Valiquett TR, Huang SM, et al. 1998. Troglitazonemonotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. J ClinEndocrinolMetab; 83:3169-3176.
[10]	Horton ES, Whitehouse F, Ghazzi MN, et al. 1998. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care; 21:1462-1469.
[11]	Mikhail N. 2006. Exenatide: a novel approach for treatment of type 2 diabetes. South Med J, 99:1271–9.
[12]	Mikhail N. 2008. Incretinmimetics and dipeptidyl peptidase inhibitors in clinical trials for the treatment of type 2 diabetes. Expert OpinInvestig Drugs, 17:845–53.
[13]	Singh AK. 2014. Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. Indian Journal of Endocrinology and Metabolism.; 18(5):617-623. doi:10.4103/2230-8210.139214.
[14]	Benjamin M. Scirica,2016. The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure. JAMA Cardiol.1(2):123-125.
[15]	Van de Laar FA, Lucassen PLBJ, Akkermans RP, et al. 2006. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst, Rev doi: 10.1002/14651858.CD005061.pub2.
[16]	http://www.nytimes.com/health/guides/disease/type-2-diabetes/medications.html.

Cite This Article

Plain Text BibTeX RIS

APA Style

Alok Raghav, Jamal Ahmad, Maaz Ozair, Saba Noor, Zeeshan Ahmad Khan, et al. (2017). Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus. International Journal of Diabetes and Endocrinology, 1(1), 13-15. https://doi.org/10.11648/j.ijde.20160101.13

Copy | Download

ACS Style

Alok Raghav; Jamal Ahmad; Maaz Ozair; Saba Noor; Zeeshan Ahmad Khan, et al. Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus. Int. J. Diabetes Endocrinol. 2017, 1(1), 13-15. doi: 10.11648/j.ijde.20160101.13

Copy | Download

AMA Style

Alok Raghav, Jamal Ahmad, Maaz Ozair, Saba Noor, Zeeshan Ahmad Khan, et al. Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus. Int J Diabetes Endocrinol. 2017;1(1):13-15. doi: 10.11648/j.ijde.20160101.13

Copy | Download

@article{10.11648/j.ijde.20160101.13,
  author = {Alok Raghav and Jamal Ahmad and Maaz Ozair and Saba Noor and Zeeshan Ahmad Khan and Brijesh Kumar Mishra},
  title = {Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {1},
  number = {1},
  pages = {13-15},
  doi = {10.11648/j.ijde.20160101.13},
  url = {https://doi.org/10.11648/j.ijde.20160101.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20160101.13},
  abstract = {Optimal successful management of type 2 diabetes mellitus (T2DM) remains an elusive goal ever. Add on therapies with metformin addressing the prime impaired insulin secretion shows promise in achieving strict and effective glycemic control. The aim of this study was to assess the efficacy of DPP-4 inhibitors, α-glucosidase inhibitors, glitazones and SGLT-2 inhibitors as add-on options with metformin to treat patients with T2DM. The primary outcome of this study was a reduction in diabetes and its associated complication along with strict glycemic control with add-on agents used with metformin.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus
AU  - Alok Raghav
AU  - Jamal Ahmad
AU  - Maaz Ozair
AU  - Saba Noor
AU  - Zeeshan Ahmad Khan
AU  - Brijesh Kumar Mishra
Y1  - 2017/01/23
PY  - 2017
N1  - https://doi.org/10.11648/j.ijde.20160101.13
DO  - 10.11648/j.ijde.20160101.13
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 13
EP  - 15
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20160101.13
AB  - Optimal successful management of type 2 diabetes mellitus (T2DM) remains an elusive goal ever. Add on therapies with metformin addressing the prime impaired insulin secretion shows promise in achieving strict and effective glycemic control. The aim of this study was to assess the efficacy of DPP-4 inhibitors, α-glucosidase inhibitors, glitazones and SGLT-2 inhibitors as add-on options with metformin to treat patients with T2DM. The primary outcome of this study was a reduction in diabetes and its associated complication along with strict glycemic control with add-on agents used with metformin.
VL  - 1
IS  - 1
ER  -

Copy | Download

Author Information

Alok Raghav

Rajiv Gandhi Centre for Diabetes & Endocrinology, J. N. Medical College, Aligarh Muslim University, Aligarh, India
Jamal Ahmad

Diabetes and Endocrinology Super Speciality Centre HIG-1 Avantika, Aligarh U.P., India
Maaz Ozair

Rajiv Gandhi Centre for Diabetes & Endocrinology J. N. Medical College, Aligarh Muslim University, Aligarh, India
Saba Noor

Rajiv Gandhi Centre for Diabetes & Endocrinology J. N. Medical College, Aligarh Muslim University, Aligarh, India
Zeeshan Ahmad Khan

Molecular Rythm Laboratory, Institute of Bio-Resources and Sustainable Development, Takyel, Imphal, Manipur, India
Brijesh Kumar Mishra

Department of Endocrinology, Guru Teg Bahardur Hospital, University of Delhi, New Delhi, India

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Alok Raghav, Jamal Ahmad, Maaz Ozair, Saba Noor, Zeeshan Ahmad Khan, et al. (2017). Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus. International Journal of Diabetes and Endocrinology, 1(1), 13-15. https://doi.org/10.11648/j.ijde.20160101.13

Copy | Download

ACS Style

Alok Raghav; Jamal Ahmad; Maaz Ozair; Saba Noor; Zeeshan Ahmad Khan, et al. Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus. Int. J. Diabetes Endocrinol. 2017, 1(1), 13-15. doi: 10.11648/j.ijde.20160101.13

Copy | Download

AMA Style

Alok Raghav, Jamal Ahmad, Maaz Ozair, Saba Noor, Zeeshan Ahmad Khan, et al. Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus. Int J Diabetes Endocrinol. 2017;1(1):13-15. doi: 10.11648/j.ijde.20160101.13

Copy | Download

@article{10.11648/j.ijde.20160101.13,
  author = {Alok Raghav and Jamal Ahmad and Maaz Ozair and Saba Noor and Zeeshan Ahmad Khan and Brijesh Kumar Mishra},
  title = {Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {1},
  number = {1},
  pages = {13-15},
  doi = {10.11648/j.ijde.20160101.13},
  url = {https://doi.org/10.11648/j.ijde.20160101.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20160101.13},
  abstract = {Optimal successful management of type 2 diabetes mellitus (T2DM) remains an elusive goal ever. Add on therapies with metformin addressing the prime impaired insulin secretion shows promise in achieving strict and effective glycemic control. The aim of this study was to assess the efficacy of DPP-4 inhibitors, α-glucosidase inhibitors, glitazones and SGLT-2 inhibitors as add-on options with metformin to treat patients with T2DM. The primary outcome of this study was a reduction in diabetes and its associated complication along with strict glycemic control with add-on agents used with metformin.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - Safety of the DPP-4 Inhibitor, α-glucosidase Inhibitors, Glitazones and SGLT-2 Inhibitors as Add-on Therapy with Metformin in Medication of Type 2 Diabetes Mellitus
AU  - Alok Raghav
AU  - Jamal Ahmad
AU  - Maaz Ozair
AU  - Saba Noor
AU  - Zeeshan Ahmad Khan
AU  - Brijesh Kumar Mishra
Y1  - 2017/01/23
PY  - 2017
N1  - https://doi.org/10.11648/j.ijde.20160101.13
DO  - 10.11648/j.ijde.20160101.13
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 13
EP  - 15
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20160101.13
AB  - Optimal successful management of type 2 diabetes mellitus (T2DM) remains an elusive goal ever. Add on therapies with metformin addressing the prime impaired insulin secretion shows promise in achieving strict and effective glycemic control. The aim of this study was to assess the efficacy of DPP-4 inhibitors, α-glucosidase inhibitors, glitazones and SGLT-2 inhibitors as add-on options with metformin to treat patients with T2DM. The primary outcome of this study was a reduction in diabetes and its associated complication along with strict glycemic control with add-on agents used with metformin.
VL  - 1
IS  - 1
ER  -

Copy | Download